Literature DB >> 12889735

Toxicity patterns of cytotoxic drugs.

Etienne Chatelut1, Jean-Pierre Delord, Pierre Canal.   

Abstract

Toxicity is a major concern for anticancer drugs. These compounds present a narrow therapeutic index, with a small difference between the dose required for an antitumor effect and that responsible for unacceptable toxicity. Their recommended doses are determined according to the toxicity endpoint. Moreover, toxicity is observed earlier than the therapeutic effect, so, toxic effects represent a major endpoint for pharmacodynamic studies of cytotoxic drugs. Knowledge of toxicity patterns and main factors of toxicity of anticancer drugs is required before modeling data of these studies. Hematological toxicities represent the main toxicity of the cytotoxic. However, non-hematological toxicities have become more important than hematological toxicities as pharmacodynamic endpoints in some circumstances such as high-dose chemotherapy associated with bone marrow transplantation. This paper will describe the main toxicity of the cytotoxic drugs, and its factors of both inter- and intra-patient variability. The toxicity pattern of topotecan will be examined as an example. Knowledge of the toxicity pattern of a drug constitutes a prerequirement before modeling its pharmacodynamics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12889735     DOI: 10.1023/a:1023565227808

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  70 in total

Review 1.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

2.  Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.

Authors:  C P Belani; C M Kearns; E G Zuhowski; K Erkmen; D Hiponia; D Zacharski; C Engstrom; R K Ramanathan; M J Capozzoli; J Aisner; M J Egorin
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

Review 3.  Oxaliplatin: a new therapeutic option in colorectal cancer.

Authors:  E Cvitkovic; M Bekradda
Journal:  Semin Oncol       Date:  1999-12       Impact factor: 4.929

4.  Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

Authors:  J L Fischel; M C Etienne; P Formento; G Milano
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

Review 5.  Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.

Authors:  C Kollmannsberger; K Mross; A Jakob; L Kanz; C Bokemeyer
Journal:  Oncology       Date:  1999       Impact factor: 2.935

6.  Modeling toxicity and response in carboplatin-based combination chemotherapy.

Authors:  M J Egorin; L M Reyno; R M Canetta; D I Jodrell; K D Swenerton; J L Pater; J N Burroughs; M J Novak; R Sridhara
Journal:  Semin Oncol       Date:  1994-10       Impact factor: 4.929

Review 7.  Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.

Authors:  R L Capizzi; W Oster
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

8.  Predicting etoposide toxicity: relationship to organ function and protein binding.

Authors:  S P Joel; R Shah; P I Clark; M L Slevin
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

Review 9.  Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).

Authors:  P D Knoester; W J Underberg; J H Beijnen
Journal:  Anticancer Res       Date:  1993 Sep-Oct       Impact factor: 2.480

10.  Mitomycin C-induced renal toxicity, a dose-dependent side effect?

Authors:  J Verwey; J de Vries; H M Pinedo
Journal:  Eur J Cancer Clin Oncol       Date:  1987-02
View more
  15 in total

Review 1.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

2.  Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme.

Authors:  Y Zhang; J Wang; H Cheng; Y Sun; M Liu; Z Wu; R Pei
Journal:  Gene Ther       Date:  2016-11-22       Impact factor: 5.250

Review 3.  Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

4.  Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.

Authors:  Patricia M Lorusso; Martin J Edelman; Susan L Bever; Karen M Forman; Maryjo Pilat; Mary F Quinn; Jing Li; Elisabeth I Heath; Lisa M Malburg; Patrick J Klein; Christopher P Leamon; Richard A Messmann; Edward A Sausville
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

5.  Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.

Authors:  Neelu Puri; Ryan T Pitman; Richard E Mulnix; Terrianne Erickson; Audra N Iness; Connie Vitali; Yutong Zhao; Ravi Salgia
Journal:  Cancer Lett       Date:  2013-09-14       Impact factor: 8.679

6.  Human topoisomerase I poisoning: docking protoberberines into a structure-based binding site model.

Authors:  Viktor Kettmann; Daniela Kost'álová; Hans-Dieter Höltje
Journal:  J Comput Aided Mol Des       Date:  2005-06-27       Impact factor: 3.686

7.  Targeted therapy in melanoma.

Authors:  Hussein Tawbi; Neelima Nimmagadda
Journal:  Biologics       Date:  2009-12-29

Review 8.  Use of cell lines in the investigation of pharmacogenetic loci.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

9.  Methanolic extracts of Uncaria rhynchophylla induce cytotoxicity and apoptosis in HT-29 human colon carcinoma cells.

Authors:  Kyung-Jin Jo; Mi-Ran Cha; Mi-Ra Lee; Mi-Young Yoon; Hae-Ryong Park
Journal:  Plant Foods Hum Nutr       Date:  2008-04-06       Impact factor: 3.921

10.  Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1.

Authors:  Yong Hoi Lee; Siew Wai Pang; Esther Revai Lechtich; Khalid Shah; Samson Eugin Simon; Suriyan Ponnusamy; Ramesh Narayanan; Chit Laa Poh; Kuan Onn Tan
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.